{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:13:48Z","timestamp":1783516428420,"version":"3.55.0"},"reference-count":37,"publisher":"Bioscientifica","issue":"1","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Reproductive age women (5\u201310%) are affected by the polycystic ovarian syndrome (PCOS), a diagnosis which confers lifelong cardiovascular and reproductive health implications. Plasminogen activator inhibitor-1 (PAI-1), the main physiological inhibitor of plasminogen activation, is consistently elevated in women with PCOS, regardless of metabolic status. Interestingly, the plasminogen system has long been implicated in proteolytic processes within the dynamic ovary. A non-physiologic elevation in PAI-1 may thus contribute systemically to endothelial dysfunction and locally to abnormal ovarian phenotype and function. We herein characterize the phenotypic alterations in ovaries from transgenic mice, which constitutively express a stable form of human PAI-1 and determine the plasma testosterone level in these mice as opposed to their unaffected counterparts. Over half of the ovaries from transgenic mice were found to contain large cystic structures, in contrast to wild-type controls of the same genetic background (53% (N = 17) vs 5% (N = 22); P = 0.001). Plasma testosterone was nearly twofold elevated in transgenic female mice versus wild-type females (0.312 ng\/ml \u00b1 0.154 (N = 10) vs 0.181 ng\/ml \u00b1 0.083 (N = 8); P = 0.014). An elevation in PAI-1 therefore appears to predispose mice to the development of this abnormal architecture, which in turn is associated with an increase in plasma testosterone. Therefore, we propose that an inappropriate elevation in PAI-1 contributes to the development of polycystic structures; these findings may thus reorient the efforts aimed at the development of therapeutic agents for the treatment of this increasingly common syndrome.<\/jats:p>","DOI":"10.1677\/jme-06-0057","type":"journal-article","created":{"date-parts":[[2007,6,29]],"date-time":"2007-06-29T13:36:57Z","timestamp":1183124217000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-6","source":"Crossref","is-referenced-by-count":42,"title":["Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice"],"prefix":"10.1530","volume":"39","author":[{"given":"Jessica K","family":"Devin","sequence":"first","affiliation":[{"name":"Divisions of Cardiovascular Medicine, 354 Preston Research Building and 1"},{"name":"Endocrinology, Diabetes and Metabolism, 715 Preston Research Building, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Nashville, Tennessee 37232, USA 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce E","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Pathology, C-3324 Medical Center North, Vanderbilt University School of Medicine, 1161 21st Avenue South, Nashville, Tennessee 37232, USA 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesut","family":"Eren","sequence":"additional","affiliation":[{"name":"Divisions of Cardiovascular Medicine, 354 Preston Research Building and 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A","family":"Gleaves","sequence":"additional","affiliation":[{"name":"Divisions of Cardiovascular Medicine, 354 Preston Research Building and 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S","family":"Bradham","sequence":"additional","affiliation":[{"name":"Divisions of Cardiovascular Medicine, 354 Preston Research Building and 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John R","family":"Bloodworth","sequence":"additional","affiliation":[{"name":"Divisions of Cardiovascular Medicine, 354 Preston Research Building and 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E","family":"Vaughan","sequence":"additional","affiliation":[{"name":"Divisions of Cardiovascular Medicine, 354 Preston Research Building and 1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2007,5,2]]},"reference":[{"key":"2026070808172929900_ADAMS-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Adams\n              JM\n            \n          , Taylor AE, Crowley WF Jr & Hall JE 2004 Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism894343\u20134350.","DOI":"10.1210\/jc.2003-031600"},{"key":"2026070808172929900_APRIDONIDZE-ETAL-2005","doi-asserted-by":"crossref","unstructured":"Apridonidze\n              T\n            \n          , Essah PA, Iuorno MJ & Nestler JE 2005 Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism901929\u20131935.","DOI":"10.1210\/jc.2004-1045"},{"key":"2026070808172929900_ATIOMO-ETAL-1998","doi-asserted-by":"crossref","unstructured":"Atiomo\n              WU\n            \n          , Bates SA, Condon JE, Shaw S, West JH & Prentice AG 1998 The plasminogen activator system in women with polycystic ovary syndrome. Fertility and Sterility69236\u2013241.","DOI":"10.1016\/S0015-0282(97)00486-X"},{"key":"2026070808172929900_BERKENPAS-ETAL-1995","doi-asserted-by":"crossref","unstructured":"Berkenpas\n              MB\n            \n          , Lawrence DA & Ginsburg D 1995 Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO Journal142969\u20132977.","DOI":"10.1002\/j.1460-2075.1995.tb07299.x"},{"key":"2026070808172929900_CHANG-AND-KATZ-1999","doi-asserted-by":"crossref","unstructured":"Chang\n              RJ\n            \n           & Katz SE 1999 Diagnosis of polycystic ovary syndrome. Endocrinology and Metabolism Clinics of North America28397\u2013408 (vii).","DOI":"10.1016\/S0889-8529(05)70076-1"},{"key":"2026070808172929900_DAHLGREN-ETAL-1992","doi-asserted-by":"crossref","unstructured":"Dahlgren\n              E\n            \n          , Janson PO, Johansson S, Lapidus L & Oden A 1992 Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstetricia et Gynecologica Scandinavica71599\u2013604.","DOI":"10.3109\/00016349209006227"},{"key":"2026070808172929900_DIAMANTI-KANDARAKIS-AND-PIPERI-2005","doi-asserted-by":"crossref","unstructured":"Diamanti-Kandarakis\n              E\n            \n           & Piperi C 2005 Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Human Reproduction Update11631\u2013643.","DOI":"10.1093\/humupd\/dmi025"},{"key":"2026070808172929900_DIAMANTI-KANDARAKIS-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Diamanti-Kandarakis\n              E\n            \n          , Palioniko G, Alexandraki K, Bergiele A, Koutsouba T & Bartzis M 2004 The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. European Journal of Endocrinology150793\u2013798.","DOI":"10.1530\/eje.0.1500793"},{"key":"2026070808172929900_EREN-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Eren\n              M\n            \n          , Painter CA, Atkinson JB, Declerck PJ & Vaughan DE 2002 Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation106491\u2013496.","DOI":"10.1161\/01.CIR.0000023186.60090.FB"},{"key":"2026070808172929900_FESTA-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Festa\n              A\n            \n          , D\u2019Agostino R Jr, Tracy RP & Haffner SM 2002 Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes511131\u20131137.","DOI":"10.2337\/diabetes.51.4.1131"},{"key":"2026070808172929900_FESTA-ETAL-2006","doi-asserted-by":"crossref","unstructured":"Festa\n              A\n            \n          , Williams K, Tracy RP, Wagenknecht LE & Haffner SM 2006 Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation1131753\u20131759.","DOI":"10.1161\/CIRCULATIONAHA.106.616177"},{"key":"2026070808172929900_GLUECK-ETAL-2006","doi-asserted-by":"crossref","unstructured":"Glueck\n              CJ\n            \n          , Sieve L, Zhu B & Wang P 2006 Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism55345\u2013352.","DOI":"10.1016\/j.metabol.2005.09.008"},{"key":"2026070808172929900_HAGGLUND-ETAL-1996","doi-asserted-by":"crossref","unstructured":"Hagglund\n              AC\n            \n          , Ny A, Liu K & Ny T 1996 Coordinated and cell-specific induction of both physiological plasminogen activators creates functionally redundant mechanisms for plasmin formation during ovulation. Endocrinology1375671\u20135677.","DOI":"10.1210\/endo.137.12.8940398"},{"key":"2026070808172929900_HARATS-ETAL-1995","doi-asserted-by":"crossref","unstructured":"Harats\n              D\n            \n          , Kurihara H, Belloni P, Oakley H, Ziober A, Ackley D, Cain G, Kurihara Y, Lawn R & Sigal E 1995 Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. Journal of Clinical Investigation951335\u20131344.","DOI":"10.1172\/JCI117784"},{"key":"2026070808172929900_HUGHESDON-1982","doi-asserted-by":"crossref","unstructured":"Hughesdon\n              PE\n            \n          \n          1982 Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called \u2018hyperthecosis\u2019. Obstetrical and Gynecological Survey3759\u201377.","DOI":"10.1097\/00006254-198202000-00001"},{"key":"2026070808172929900_JONARD-AND-DEWAILLY-2004","doi-asserted-by":"crossref","unstructured":"Jonard\n              S\n            \n           & Dewailly D 2004 The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Human Reproduction Update10107\u2013117.","DOI":"10.1093\/humupd\/dmh010"},{"key":"2026070808172929900_KERO-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Kero\n              JT\n            \n          , Savontaus E, Mikola M, Pesonen U, Koulu M, Keri RA, Nilson JH, Poutanen M & Huhtaniemi IT 2003 Obesity in transgenic female mice with constitutively elevated luteinizing hormone secretion. American Journal of Physiology. Endocrinology and Metabolism285E812\u2013E818.","DOI":"10.1152\/ajpendo.00367.2002"},{"key":"2026070808172929900_KRAVARITI-ETAL-2005","doi-asserted-by":"crossref","unstructured":"Kravariti\n              M\n            \n          , Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A, Paraskevaidis EA, Chrousos GP, Tsatsoulis A & Michalis LK 2005 Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism905088\u20135095.","DOI":"10.1210\/jc.2005-0151"},{"key":"2026070808172929900_KYEI-MENSAH-ETAL-1998","doi-asserted-by":"crossref","unstructured":"Kyei-Mensah\n              AA\n            \n          , LinTan S, Zaidi J & Jacobs HS 1998 Relationship of ovarian stromal volume to serum androgen concentrations in patients with polycystic ovary syndrome. Human Reproduction131437\u20131441.","DOI":"10.1093\/humrep\/13.6.1437"},{"key":"2026070808172929900_LEGRO-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Legro\n              RS\n            \n          , Castracane VD & Kauffman RP 2004 Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstetrical and Gynecological Survey59141\u2013154.","DOI":"10.1097\/01.OGX.0000109523.25076.E2"},{"key":"2026070808172929900_LIJNEN-2005","doi-asserted-by":"crossref","unstructured":"Lijnen\n              HR\n            \n          \n          2005 Pleiotropic functions of plasminogen activator inhibitor-1. Journal of Thrombosis and Haemostasis335\u201345.","DOI":"10.1111\/j.1538-7836.2004.00827.x"},{"key":"2026070808172929900_LIU-2004","doi-asserted-by":"crossref","unstructured":"Liu\n              YX\n            \n          \n          2004 Plasminogen activator\/plasminogen activator inhibitors in ovarian physiology. Frontiers in Bioscience93356\u20133373.","DOI":"10.2741\/1487"},{"key":"2026070808172929900_LIU-ETAL-1996","doi-asserted-by":"crossref","unstructured":"Liu\n              K\n            \n          , Brandstrom A, Liu YX, Ny T & Selstam G 1996 Coordinated expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 during corpus luteum formation and luteolysis in the adult pseudopregnant rat. Endocrinology1372126\u20132132.","DOI":"10.1210\/endo.137.5.8612557"},{"key":"2026070808172929900_LIU-ETAL-1997","doi-asserted-by":"crossref","unstructured":"Liu\n              K\n            \n          , Liu YX, Hu ZY, Zou RY, Chen YJ, Mu XM & Ny T 1997 Temporal expression of urokinase type plasminogen activator, tissue type plasminogen activator, plasminogen activator inhibitor type 1 in rhesus monkey corpus luteum during the luteal maintenance and regression. Molecular and Cellular Endocrinology133109\u2013116.","DOI":"10.1016\/S0303-7207(97)00152-4"},{"key":"2026070808172929900_LIU-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Liu\n              YX\n            \n          , Liu K, Feng Q, Hu ZY, Liu HZ, Fu GQ, Li YC, Zou RJ & Ny T 2004 Tissue-type plasminogen activator and its inhibitor plasminogen activator inhibitor type 1 are coordinately expressed during ovulation in the rhesus monkey. Endocrinology1451767\u20131775.","DOI":"10.1210\/en.2003-1327"},{"key":"2026070808172929900_LO-ETAL-2006","doi-asserted-by":"crossref","unstructured":"Lo\n              JC\n            \n          , Feigenbaum SL, Yang J, Pressman AR, Selby JV & Go AS 2006 Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism911357\u20131363.","DOI":"10.1210\/jc.2005-2430"},{"key":"2026070808172929900_ORIO-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Orio\n              F\n            \n           Jr, Palomba S, Cascella T, Tauchmanova L, Nardo LG, Di BS, Labella D, Russo T, Savastano S, Tolino A et al.2004 Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reproductive Biomedicine Online9505\u2013510.","DOI":"10.1016\/S1472-6483(10)61634-3"},{"key":"2026070808172929900_PENG-ETAL-1993","doi-asserted-by":"crossref","unstructured":"Peng\n              XR\n            \n          , Hsueh AJ & Ny T 1993 Transient and cell-specific expression of tissue-type plasminogen activator and plasminogen-activator-inhibitor type 1 results in controlled and directed proteolysis during gonadotropin-induced ovulation. European Journal of Biochemistry214147\u2013156.","DOI":"10.1111\/j.1432-1033.1993.tb17907.x"},{"key":"2026070808172929900_PIERPOINT-ETAL-1998","doi-asserted-by":"crossref","unstructured":"Pierpoint\n              T\n            \n          , McKeigue PM, Isaacs AJ, Wild SH & Jacobs HS 1998 Mortality of women with polycystic ovary syndrome at long-term follow-up. Journal of Clinical Epidemiology51581\u2013586.","DOI":"10.1016\/S0895-4356(98)00035-3"},{"key":"2026070808172929900_RISMA-ETAL-1995","doi-asserted-by":"crossref","unstructured":"Risma\n              KA\n            \n          , Clay CM, Nett TM, Wagner T, Yun J & Nilson JH 1995 Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. PNAS921322\u20131326.","DOI":"10.1073\/pnas.92.5.1322"},{"key":"2026070808172929900_SAMPSON-ETAL-1996","doi-asserted-by":"crossref","unstructured":"Sampson\n              M\n            \n          , Kong C, Patel A, Unwin R & Jacobs HS 1996 Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clinical Endocrinology45623\u2013629.","DOI":"10.1046\/j.1365-2265.1996.00863.x"},{"key":"2026070808172929900_SILLS-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Sills\n              ES\n            \n          , Drews CD, Perloe M, Tucker MJ, Kaplan CR & Palermo GD 2003 Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system. Gynecological Endocrinology17231\u2013237.","DOI":"10.1080\/gye.17.3.231.237"},{"key":"2026070808172929900_DETAEYE-ETAL-2005","doi-asserted-by":"crossref","unstructured":"DeTaeye\n              B\n            \n          , Smith LH & Vaughan DE 2005 Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Current Opinion in Pharmacology5149\u2013154.","DOI":"10.1016\/j.coph.2005.01.007"},{"key":"2026070808172929900_TAKAHASHI-ETAL-1994","doi-asserted-by":"crossref","unstructured":"Takahashi\n              K\n            \n          , Eda Y, bu-Musa A, Okada S, Yoshino K & Kitao M 1994 Transvaginal ultrasound imaging, histopathology and endocrinopathy in patients with polycystic ovarian syndrome. Human Reproduction91231\u20131236.","DOI":"10.1093\/oxfordjournals.humrep.a138684"},{"key":"2026070808172929900_TARKUN-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Tarkun\n              I\n            \n          , Canturk Z, Arslan BC, Turemen E & Tarkun P 2004 The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocrine Journal51467\u2013472.","DOI":"10.1507\/endocrj.51.467"},{"key":"2026070808172929900_VAUGHAN-2005","doi-asserted-by":"crossref","unstructured":"Vaughan\n              DE\n            \n          \n          2005 PAI-1 and atherothrombosis. Journal of Thrombosis and Haemostasis31879\u20131883.","DOI":"10.1111\/j.1538-7836.2005.01420.x"},{"key":"2026070808172929900_WILD-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Wild\n              S\n            \n          , Pierpoint T, McKeigue P & Jacobs H 2000 Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clinical Endocrinology52595\u2013600.","DOI":"10.1046\/j.1365-2265.2000.01000.x"}],"container-title":["Journal of Molecular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/jme\/article-pdf\/39\/1\/9\/65425\/0390009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/jme\/article-pdf\/39\/1\/9\/65425\/0390009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:17:38Z","timestamp":1783513058000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/jme\/article\/39\/1\/9\/11240\/Transgenic-overexpression-of-plasminogen-activator"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,7,1]]}},"URL":"https:\/\/doi.org\/10.1677\/jme-06-0057","relation":{},"ISSN":["1479-6813","0952-5041"],"issn-type":[{"value":"1479-6813","type":"electronic"},{"value":"0952-5041","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5,2]]}}}